Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Gains from Investment Securities (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Gains from Investment Securities data on record, last reported at $16000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $16000.0; the TTM value through Sep 2025 reached $68000.0, up 334.48%, while the annual FY2024 figure was $311000.0, 148.8% up from the prior year.
  • Gains from Investment Securities reached $16000.0 in Q3 2025 per BTAI's latest filing, up from $1000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $122000.0 in Q2 2022 and bottomed at -$29000.0 in Q2 2023.
  • Average Gains from Investment Securities over 4 years is $28755.5, with a median of $16000.0 recorded in 2025.
  • Peak YoY movement for Gains from Investment Securities: tumbled 2313.74% in 2023, then skyrocketed 275.86% in 2024.
  • A 4-year view of Gains from Investment Securities shows it stood at $1310.0 in 2022, then crashed by 2313.74% to -$29000.0 in 2023, then surged by 275.86% to $51000.0 in 2024, then tumbled by 68.63% to $16000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $16000.0 in Q3 2025, $1000.0 in Q1 2025, and $51000.0 in Q4 2024.